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http://dx.doi.org/10.1016/j.kjms.201Abstract Although the pathological mechanism underlying kidney damage is not completely
understood, it has been reported that reactive oxygen species (ROS) formed during ureteral
obstruction may play an important role in this process. Carvedilol has been used in a limited
number of studies examining oxidative injury. The aim of this study was to investigate the
effect of carvedilol on serum and tissue oxidative stress parameters in the partial unilateral
ureteral obstruction (PUUO)-induced rat model. To our knowledge, the protective effects of
carvedilol in the PUUO-induced rat model have not been reported. Twenty-six male Wistar
albino rats, age 5.5 to 6 months and weighing 250 to 300 g, were used in this study. The rats
were randomly divided into three groups. In Group 1 (nZ 9), the control group, a sham oper-
ation was performed. In Group 2 (nZ 8), the PUUO group, the left ureter was embedded into
the psoas muscle to create PUUO and maintained for 7 days. In Group 3 (nZ 9), carvedilol was
orally administered to the rats (2 mg/kg). After the establishment of PUUO, carvedilol was
given for the following 7 days. After partial unilateral ureteral obstruction, a nephrectomy
was performed to determine the blood and tissue levels of superoxide dismutase (SOD), mal-
ondialdehyde (MDA), protein carbonyl (PC), and nitric oxide (NO). The median SOD, MDA, PC,
and NO levels in the tissues were 0.006 U/mg protein, 5.11 nmol/g protein, 4.31 nmol/mg
protein, and 0.337 mmol/g protein in the control group, respectively. There was a significant
increase in tissue SOD (p Z 0.014), MDA (p Z 0.002), and NO (p Z 0.004) levels in Group 2.
However, a statistically significant difference was not observed in PC (p Z 0.847) enzymatic
activity in Group 2. When compared with Group 2, carvedilol treatment caused a reduction
in NO (p Z 0.003), and PC (p Z 0.001) activities in Group 3. The serum SOD (p Z 0.004),. Geksi Cad, 4. Sok. No:3, Altınıs‚ık Apt. A Blok, K:1, D:2, Merkez/TOKAT 60100, Turkey.
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20 A. Yasar et al.MDA (p Z 0.043), PC (p Z 0.043), and NO (p Z 0.001) levels were significantly different in
Group 3 compared with Group 2. Administration of carvedilol also reduced the detrimental
histopathologic effects caused by PUUO. According to histopathological examination of the
renal tissues, the inflammation rates were 22.2%, 87.5% and 33.3% in Groups 1, 2, and 3,
respectively (p < 0.05). The results of the present study show that partial unilateral ureteral
obstruction caused oxidative stress in the serum and kidney tissues of rats, and treatment with
carvedilol reduced the harmful effects of ureteral obstruction.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Figure 1. Partial unilateral ureteral obstruction-induced rat
model (arrowheads).Introduction
Ureteral obstruction may result from various intraluminal
and extraluminal causes including retroperitoneal fibrosis,
trauma, blood clots, tumors, and foreign materials. In
addition, ureteral obstruction can be observed due to intra-
abdominal surgical operations such as caesarean section,
hysterectomy and colonic surgery. Ureteral obstruction has
also been implicated in renal parenchymal damage [1e4].
Although partial unilateral ureteral obstruction (PUUO) is
one of the most common urologic problems, the patho-
physiologic changes in renal tissue due to PUUO are not
understood. Known factors in the pathophysiology of renal
obstructive parenchymal injury include renal blood flow
impairment, intrapelvic pressure elevation, vasoactive and
inflammatory mediators such as activation of renin angio-
tensin system, expression of transforming growth factor-
a (TGF-a), clusterin, Fas ligand, kaspase and catalase
activity, N-acetyl-b-glucosaminidase, b2 microglobulin, g-
glutamyl transferase, a-glycosidase, endothelial growth
factor (EGF), and prostaglandins [5e10]. Recently, it has
been suggested that reactive oxygen species (ROS), which
are formed during ureteral obstruction, may play a role in
this process. Antioxidant agents have been used to prevent
the negative effects of ROS on serum and tissue oxidative
parameters [11,12].
Carvedilol is a nonselective b-blocker with additional a-
blocker properties. Carvedilol competitively blocks a-1, b-
1, and b-2 adrenergic receptors and also has vasodilatory
properties. It has been commonly used for the clinical
treatment of congestive heart failure, hypertension and
myocardial infarction [13e15]. In addition to its anti-
adrenergic effects, carvedilol also has antioxidant proper-
ties. Due to its antioxidant properties, carvedilol can treat
many pathologic conditions that are associated with
enhanced cellular oxidative stress [13e16]. Currently, the
relationship between the oxidative stress in the kidneys and
treatment with antioxidants in the PUUO-induced rat model
has been shown in a very limited number of studies. To our
knowledge, the protective effects of carvedilol in the
PUUO-induced rat model has not been studied.
The aim of this study was to evaluate the effects of
carvedilol on antioxidant enzyme levels and histopathologic
changes in the PUUO-induced rat kidney.
Materials and methods
After obtaining approval from the local ethics committee
(2010-HADYEK-042), a total of twenty-six male Wistaralbino rats, age 5.5 to 6 months and weighing 250 to 300 g,
were used in the study. The rats were handled in the
laboratory according to the Guide for Care and Use of
Laboratory Animals of the National Research Council as
well as institutional guidelines. The rats were kept in
a temperature-controlled room (20C to 23C) on a 12-hour
light/dark cycle with food (commercial rat chow) and fresh
water available ad libitum. All surgical procedures were
performed under xylazine/ketamine anesthesia under
sterile conditions. All rats were sacrificed after the exper-
imental procedures. The rats were randomly divided into
three groups. Group 1 (nZ 9) was designated as the control
group. These sham-operated rats had undergone lapa-
rotomy through the abdominal midline incision, and their
ureters were manipulated but not ligated. The rats in this
group were used to determine basal values for biochemical
and tissue evaluation. Group 2 (nZ 8) was designed to see
the effects of PUUO on serum and renal tissue oxidative
stress parameters. In this group, PUUO was performed with
two-thirds of the left ureter embedded in the psoas muscle
with 4-0 silk through a midline abdominal incision, as
previously described in the literature [17] (Fig. 1). Group 3
(n Z 9) was designed to determine the effect of carvedilol
on serum and tissue oxidative stress parameters after
PUUO. In this group, after PUUO was performed, carvedilol
was given to the rats orally (2 mg/kg). Carvedilol was
administered to the rats for 7 days after the establishment
of PUUO. At the end of the experiment, left-sided
nephrectomies were performed for all the rats in Groups
2 and 3 for histopathologic and biochemical analysis. The
tissue levels of oxidative stress parameters, such as
Figure 3. Multifocal lymphocytic infiltration observed as two
very small foci in the interstitium of the rat kidney (arrow; HE,
15).
Carvedilol and ureteral obstruction 21malondialdehyde (MDA), superoxide dismutase (SOD),
protein carbonyl (PC), and nitric oxide (NO), were studied
in all groups. The serum levels of the same parameters
were also studied in the blood, 5 ml of which was drawn
from the vena cava inferior of all the rats immediately prior
to sacrifice.
The data were analyzed using SPSS for Windows soft-
ware. A p-value <0.05 was considered statistically signifi-
cant. For statistical analysis, Mann-Whitney U test and Chi-
square tests were performed.
Histopathologic examination
Approximately half of the nephrectomy specimens were
embedded into formaldehyde solution for pathologic
examinations, while the biochemical studies were per-
formed with the other half. All histologic analysis were
performed in routinely processed formalin-fixed, paraffin-
embedded tissue sections (4 mm thick), which were stained
with hematoxylin-eosin; the slides were examined with
a light microscope under 20x magnification. Randomly
selected fields were evaluated for cellular and tubular
structures. Using pathologic examination, interstitial
inflammation was evaluated. A semi-quantitative grading
system was used for each parameter. The inflammation
process was graded as mild (þ1), moderate (þ2) or severe
(þ3). Interstitial mononuclear cell infiltration with one
small focus was accepted as mild inflammation (Fig. 2). If
the mononuclear cell infiltration was detected in more than
one focus in the interstitia, it was accepted as moderate
inflammation (Fig. 3). Finally, severe inflammation was
evident when mononuclear inflammatory cell infiltration
with large aggregates was observed (Fig. 4).
Biochemical analyses
Blood samples were drawn into heparin-free tubes for
biochemical analyses. After centrifugation (3000  g for
15 min at þ4C), serum samples were stored frozen at
e70C. Determinations of the following parameters were
made in the serum samples using commercial chemicals
supplied by Sigma (St Louis, MO, USA) (17).Figure 2. Pericapillary lymphocytic infiltration observed as
a very small focus in the interstitium of the rat kidney (arrow;
HE, 30).Serum antioxidant enzyme analysis
Determination of SOD activity
Total (CueZn and Mn) SOD (EC 1.15.1.1) activity was
determined according to the method described by Sun et al.
[18]. The method is based on inhibition of nitroblue tetra-
zolium (NBT) reduction by the xanthineexanthine oxidase
system as a superoxide generator. Activity was assessed in
the ethanol phase of the supernatant after 1.0 ml of an
ethanolechloroform mixture (5:3, v/v) was added to the
same volume of sample and centrifuged. One unit of SODwas
defined as the amount causing 50% inhibition in the NBT
reduction rate. The SOD activity was expressed as U/mL in
the tissue and U/mg protein in the serum.
Determination of MDA levels
The tissue thiobarbituric acid-reactive substance (TBARS)
level was determined by a method [19] based on reaction
with thiobarbituric acid (TBA) at 90C to 100C. In the TBAFigure 4. Lymphocytic infiltration observed as a large
aggregate in the interstitium of the rat kidney (arrow; HE,
20).
22 A. Yasar et al.test reaction, MDA or MDA-like substances and TBA react to
produce a pink pigment with an absorption maximum at
532 nm. The reaction was performed at pH 2 to 3 and 90C
for 15 minutes. The sample was mixed with two volumes of
cold 10% (w/v) trichloroacetic acid to precipitate the
protein. The precipitate was pelleted by centrifugation,
and an aliquot of the supernatant was reacted with an
equal volume of 0.67% (w/v) TBA in a boiling water-bath for
10 min. After cooling, the absorbance was read at 532 nm.
The results were expressed as mmol/L in the tissue
and nmol/g protein in the serum, according to the standard
graphic prepared from measurements with a standard
solution (1,1,3,3 tetramethoxypropane) [19].
Determination of tissue PC content
The carbonyl contents were determined spectrophotomet-
rically, based on the reaction of the carbonyl group with 2,
4-dinitrophenylhydrazine to form 2,4-dinitrophenylhy-
drazone. 2,4-Dinitrophenylhydrazine was the reagent orig-
inally used for proteins subjected to metal-catalyzed
oxidation. The results were given as nmol/ml in the tissue
and nmol/mg protein in the serum [20,21].
NO determination
NO measurement is very difficult in biological specimens;
therefore, tissue nitrite (NO2
) and nitrate (NO3
) were
estimated as an index of NO production. The samples were
initially deproteinized with Somogyi reagent. Total nitrite
(nitrite þ nitrate) was measured after conversion of nitrate
to nitrite by copperized cadmium granules using a spectro-
photometer at 545 nm. A standard curve was established
with a set of serial dilutions (108 to 103 mol/L) of sodium
nitrite. Linear regression was carried out using the peak
area from the nitrite standard. The resulting equation was
then used to calculate the unknown sample concentrations.
The results were expressed as mmol/L in the tissue and
mmol/L in the serum [22].
Results
The median serum levels of MDA, NO, and PC were
2.327 mmol/L, 155.6 mmol/L, and 2860 nmol/ml in Group 1,
respectively. The serum levels of MDA, NO, and PC
increased in the PUUO group compared with the control
group; however, only the difference between MDA and NO
was statistically significant (p < 0.05). Carvedilol treatment
ameliorated serum MDA, NO and PC levels in Group 3.Table 1 The median levels of the reactive oxygene species are
Groups SOD U/mg protein MDA nmol/g prote
Group 1 0.006 5.11
Group 2 0.0095 9.05
p 0.014 0.002
Group 2 0.0095 9.05
Group 3 0.008 6.56
p 0.585 0.083
MDA Z malondialdehyde; NO Z nitric oxide; PC Z protein carbonyl;Similarly, antioxidant enzyme activity (SOD) increased in
the PUUO group. Carvedilol treatment caused decreased
SOD activity compared with the sham-operated control
group (p < 0.05). The results of blood SOD, MDA, NO, and PC
values in all three groups are shown in Table 2. The renal
tissue levelsofMDA,NO,andPCweredetectedas5.11nmol/g
protein, 0.337 mmol/g protein and 4.31 nmol/mg protein, in
Group 1, respectively. The renal tissue levels of MDA and
NO increased in the PUUO group compared with the
sham-operated group (p < 0.05). However, a statistically
significant difference was observed in PC and NO enzyme
activities in Group 3. Antioxidant enzyme activities (SOD)
were increased in the PUUO group. In Group 3, carvedilol
treatment caused decreased SOD, MDA, NO, and PC
levels, compared with the sham-operated control group.
The results of renal tissue SOD, MDA, NO and PC values in
all groups are shown in Table 1. The renal inflammation
rates were 22.2%, 87.5%, and 33.3% in Groups 1, 2, and 3,
respectively (p < 0.05). The inflammation severity was
mild (þ1) in two rats (22.2%) in Group 1. In this group,
moderate or severe inflammation was not detected.
However, mild (þ1), moderate (þ2) and severe (þ3)
inflammation rates were 37.5% (n Z 3), 37.5% (n Z 3),
and 12.5% (n Z 1) in Group 2, respectively. In Group 3,
only three (33.3%) mild inflammation rates were detec-
ted. Inflammation rates were increased in the PUUO
group compared with Group 1, and carvedilol treatment
caused decreased inflammation rates (p < 0.05).Discussion
Urinary tract obstruction is a common problem in the
practice of urology and can occur at any location along the
urinary tract. The occurance of urinary tract obstruction is
most often secondary to calculi, tumors, strictures, ure-
teropelvic junction obstruction or ureterovesical junction
obstruction, ectopic ureter, ureterocele, megaureter, and
posterior urethral valves. Ureteral obstruction frequently
occurs unilaterally and is usually a reversible condition
[1,2,23]. Although ureteral obstructions may cause renal
parenchymal damage due to several mechanisms, the exact
pathophysiologic mechanism of the kidney damage is
complex and has not been fully understood. Obstructive
uropathy leads to functional and morphological changes in
the kidney. If the ureteral obstruction persists, tubular
atrophy, interstitial fibrosis, ischemia, and necrosis may
occur. Although pressure increases and ischemic atrophy
have been implicated in the pathogenesis of urinary tract
obstructions in recent studies, vasoconstriction andseen in renal tissue.
in NO mmol/g protein PC nmol/mg protein
0.337 4.31
0.433 3.89
0.004 0.847
0.433 3.89
0.312 2.54
0.003 0.001
SOD Z superoxide dismutase.
Table 2 The comparison of the serum reactive oxygen levels in all groups.
Groups SOD U/mL MDA mmol/L NO mmol/L PC nmol/ml
Group 1 1.475 2.327 155.6 2860
Group 2 1.803 2.745 204.3 3320
P 0.144 0.038 0.001 0.149
Group 2 1.803 2.745 204.3 3320
Group 3 1.311 2.353 152.5 2950
P 0.004 0.043 0.001 0.043
MDA Z malondialdehyde; NO Z nitric oxide; PC Z protein carbonyl; SOD Z superoxide dismutase.
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the pathogenesis of kidney damage in ureteral obstructions
[3,7,23]. Associated with this situation, it has been re-
ported that many molecular and biochemical factors
including oxidative stress may also play a role in the path-
ophysiology of the parenchymal kidney damage in ureteral
obstruction [3,7e10,23]. Oxidative stress is a condition
related to an increased rate of cellular damage induced by
oxygen and oxygen-derived oxidants commonly known as
ROS [24]. ROS are intermediary metabolites that are nor-
mally produced in the course of oxygen metabolism. Under
normal conditions, ROS play a critical role as signaling
molecules. However, the overexpression of ROS can avidly
react with and denature proteins, lipids, nucleic acids,
carbohydrates and other molecules, as well as cause
inflammation, apoptosis, fibrosis, and cell proliferation
[25]. ROS can disrupt the functional state and integrity of
the cell membrane by lipid peroxidation reaction. In the
literature it is reported that, in various conditions such as
ischemiaereperfusion injury, arthritis, cancer, diabetes
mellitus, and central nervous system disorders, ROS may
lead to severe injury in the cell membrane by lipid perox-
idation reactions [26]. In addition to the above disorders,
ROS are thought to play a role in the tubulointerstitial
inflammation process in PUUO-induced rat models [27].
Indeed, in recent studies it has been demonstrated that
antioxidant enzyme activities were diminished and ROS
production was increased during ureteral obstruction [28].
All of these changes occur secondary to PUUO and may
contribute to tubulointerstitial damage and fibrosis. In the
present study, serum and tissue levels of MDA and NO
significantly increased in PUUO-induced rat group
compared with the control group. A study by Demirbilek
et al. showed that oxidative stress products, antioxidants
and lipid peroxidation levels in the PUUO group were
significantly different from the levels in the control group
[29]. Similar findings have been reported by other authors
in the PUUO-induced rat model [30,31].
The most important strategy to reduce ROS is antioxidant
use. Both biological and chemical antioxidants are
compounds that scavenge ROS and/or suppress their
production and actions. The beneficial effects of antioxi-
dants on oxidative stress parameters and different tissues in
oxidative stress conditions have been reported in numerous
previous studies. In this context, to prevent the harmful
effects of oxidative stress, many antioxidant agents such as
vitamin E, melatonin, retinol, b-carotene, omega-3, resver-
atrol, vitamin C, coenzyme Q10, and acetylcysteine have
been used with different success rates [6,8,32e34]. Addi-
tionally, the beneficial effects of antioxidants have beenshown in the prevention and management of coronary heart
disease, cancer, hypertension, type 2 diabetes mellitus,
renal diseases, rheumatoid arthritis, ulcerative colitis,
Crohn’s disease, and chronic obstructive pulmonary disease
[6,8,26]. Moreover, many experimental animal studies have
confirmed the efficacy of antioxidants in reducing the short-
term detrimental effects of obstruction on the kidney
[12,35]. In a PUUO-induced ratmodel, Fitzgerald et al. found
that the administration of atorvastatin decreased the grade
of kidney injury histologically [12]. Similarly, in another
study, Ozbek et al. investigated the effects of melatonin on
PUUO-induced kidney injury and reported that melatonin
exerted a preventive effect on oxidative stress with an
eventual decrease in PUUO-induced kidney injury. According
to these results, the authors claimed that melatonin dimin-
ished thedestructiveeffectofROSandcanbeused toprotect
kidney from the harmful effects of PUUO [31]. The beneficial
effects of some other antioxidants, such as L-carnitine and
tocopherol, on PUUO-induced rat kidney had also been
shown by authors in previous studies [12,36].
Carvedilol is a lipophilic, third-generation, nonselective
b-adrenoceptor and selective a-1-adrenoceptor blocker
[13,14]. In addition to its b-blocker and a-blocker activities,
carvedilol and some of its metabolites, such as SB 211475
and SB 209995, are potent antioxidants. This activity has
been attributed to the carbazole moiety of this drug. For
this reason, several experimental studies have demon-
strated that the administration of carvedilol can attenuate
the negative effects of oxidative stress under different
conditions. The inhibitory effects of carvedilol on lipid
peroxidation have been shown in various systems and cell
groups [13,16]. For example, in a recent study, chronic
administration of carvedilol resulted in attenuation of
oxidative damage in the streptozotocin-induced model of
dementia in rats [37]. In addition, it has been suggested
that carvedilol may play a potential role in the treatment of
neurodegenerative diseases. Moreover, it has been shown
that carvedilol inhibits the release of superoxide ions from
activated neutrophils. Due to the recognized role of
superoxide anions in postischemic tissue injury, it has been
suggested that carvedilol and SB-211475 could prevent the
formation of more toxic oxidants and thus reduce oxidative
tissue injury [38] through their scavenging activity against
superoxide anions. In another study, Hayashi et al. inves-
tigated the effects of carvedilol on ischemia reperfusion
injury in rats. In this study, the authors detected that serum
creatinine levels were higher in the control group compared
with the carvedilol treatment group on postoperative Days
2 and 4. According to these results, the authors emphasized
that increased antioxidant modulation by carvedilol
24 A. Yasar et al.attenuated renal ischemia reperfusion injury [39]. In
another similar study using the renal ischemia reperfusion-
induced rat model, the pretreatment of animals with car-
vedilol attenuated renal dysfunction led to decreased
morphological alterations and restored the depleted renal
antioxidant enzymes. In that study, the authors also
detected that the renal function and morphological damage
significantly improved by carvedilol administration [40].
Similarly, in our study, the administration of carvedilol
attenuated ROS levels and minimized oxidative stress
induced by PUUO in the kidney. The administration of
carvedilol also reduced the detrimental histopathologic
effects caused by PUUO. As a consequence, according to
the results of these studies, the antioxidant effects of
carvedilol was explained by three mechanisms: (1) inhibi-
tion of direct cytotoxic actions of free radicals; (2)
prevention of oxygen-free radicals from activated tran-
scription factors such as NF-kB; and (3) protection and
replenishment of the endogeneous antioxidant defense
mechanisms, GSH-PX, and vitamin E [41].
As a result, our study was the first study to evaluate the
potential protective effects of carvedilol against oxidative
stress in PUUO-induced rat kidneys. According to the results
of this study,we suggest that the administration of carvedilol
may attenuate the effects of oxidative stress in the PUUO-
induced rat kidney. In addition, although this is an animal
study, it can be speculated that carvedilol may be used
clinically as an antioxidant agent in ureteral obstruction to
minimize or prevent paranchymal damage in the kidney.References
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